$6.68
-0.49-6.83%
Last update: Oct 23, 7:33 PM
Regenxbio Inc (RGNX) Stock Price, Quote, News & History
RGNXNASDAQ
Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.
You can purchase shares of Regenxbio (NASDAQ:RGNX) through any online brokerage.
Other companies in Regenxbio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Regenxbio has a consensus price target of $23.67.
The stock price for Regenxbio (NASDAQ: RGNX) is $6.73 last updated October 23, 2026 at 7:33 PM EDT.
There are no upcoming dividends for Regenxbio.
Regenxbio does not have any upcoming earnings scheduled.
There is no upcoming split for Regenxbio.
Regenxbio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins....
